EpiSwitch COVID-19 Severity Test
Many people have questions about how COVID-19 may affect them. “What will happen if I get infected?” “Will I have a severe immune response?” “I am at risk for being hospitalized?”
EpiSwitch CST is the first and only commercially-available blood test for the prediction of COVID-19 severity in ANY adult, independent of COVID-19 status.
The test is designed to provide healthcare professionals (HCPs) and their adult patients with actionable decision-making information regarding infection mitigation during the COVID-19 pandemic based on the unique 3D genetic immune profile of each individual.
Benefits of EpiSwitch CST
ENHANCED, PERSONALIZED GUIDANCE
PREDICT RESPONSE TO INFECTION IN ANY ADULT
HIGH CONFIDENCE FOR HCPs
Features of EpiSwitch CST
EpiSwitch CST helps adults understand and cope with the risks that COVID-19 poses to them.
The EpiSwitch CST report provides HCPs and their patients with an easy-to-understand molecular assessment of risk for a severe immune response to COVID-19.
EpiSwitch CST Report
The EpiSwitch CST report includes clear guidance for HCPs to interpret an adult patient’s risk score and formulate an effective management plan.
Individuals with an EpiSwitch CST score >75% are at increased probability of experiencing a severe immune response, also known as an immune-storm reaction, to COVID-19. Such individuals should be counseled on their risk level and may benefit from a mitigation-strategy review to avoid infection. In the event of infection, early use of medications or other interventions are recommended.
Those at average risk should not be construed as having no risk; complications that do not require critical care are possible.
Risk results do not provide information about an individual’s risk of becoming infected. Regardless of risk results, government and local health-department guidelines must be followed to avoid transmitting the virus.
Existing COVID-19 tests fall into two general categories. The first category detects the presence of the SARS-CoV-2 virus and diagnoses an active coronavirus infection. The second category detects antibodies generated by the immune system in response to and provide an indication of past coronavirus infection.
EpiSwitch CST gives your healthcare provider (HCP) forward-looking information about your risk of developing a severe immune reaction that may require hospitalization if you become infected with the SARS-CoV-2 virus.
EpiSwitch CST assigns individuals as either high-risk or average-risk. Individuals at high-risk are significantly more likely to have a critical immune-system response, also known as an immune-storm reaction, following infection and may benefit from an infection mitigation-strategy review, and, in the event of infection, early use of medications or other interventions. Those at average risk should not be construed as having no risk; complications that do not require critical care are possible.
NOTE: Risk results do not provide information about an individual’s risk of becoming infected. Regardless of risk results, government and local health department guidelines must be followed to avoid transmitting the virus.
CLIA, Clinical Laboratory Improvement Amendments.